Clarithromycin

Class: Macrolide

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Covers a wide array of Gram-positive and Gram-negative bacteria. Also an effective anti-mycobacterial.
Institute where first reported:	Taisho Pharmaceutical, Japan
Year first mentioned:	1980
Highest developmental phase:	Approved by FDA in 1991
Development status:	Approved
Reason Dropped:	Other formulations have been discontinued

Chemical structure(s):
Canonical SMILES:	CC[C@@H]1[C@](C)([C@@H]([C@@H](C)C(=O)[C@H](C)C[C@](C)([C@@H]([C@@H](C)[C@@H]([C@@H](C)C(=O)O1)O[C@H]2C[C@](C)([C@H]([C@H](C)O2)O)OC)O[C@H]3[C@@H]([C@H](C[C@@H](C)O3)N(C)C)O)OC)O)O
Isomeric SMILES:	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
InChI:	InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
InChI Key:	AGOYDEPGAOXOCK-KCBOHYOISA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/84029

External links:
Guide to Pharmacology:	clarithromycin
Main Source:	https://www.drugs.com/monograph/clarithromycin.html
Citation:	https://aac.asm.org/content/64/5/e02349-19